Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes
American Journal of Physiology-Cell Physiology · 2026-09-01 · 331 (3) · C825-C833
DOI: 10.1152/ajpcell.00526.2025 ↗Abstract
Urinary C3M is a dynamic biomarker of ECM turnover with pharmacodynamic relevance in kidney disease. Previous studies in diabetic and nondiabetic kidney disease have shown that therapeutic interventions can increase urinary C3M levels. Here, compared with RASi monotherapy, GLP-1 RA-based combination therapy with RASi was associated with a more favorable longitudinal urinary C3M trajectory and an altered association between urinary C3M and kidney function in type 2 diabetes.
EUVIMED